InflaRx (IFRX) Stock Forecast & Price Target

InflaRx is viewed positively because izicopan appears to offer a differentiated, potentially best-in-class oral C5aR profile in AAV, with better PK/PD, more convenient dosing, and no SAEs or TEAEs reported in more than 180 dosed subjects. The thesis is strengthened by Tavneos’ commercial success, which validated the mechanism and reached $643M in 2025 worldwide AAV sales, yet now faces hepatotoxicity concerns, monthly liver monitoring, and serious regulatory scrutiny that could create share-shift opportunity. Financially, the company ended 2Q26 with no debt and about €158M cash, which analysts view as sufficient through 2029, while physician survey data showed 69% would switch to an izicopan-like profile and 92% would increase C5aR prescribing.

InflaRx is facing a weak fundamental setup because Gohibic (vilobelimab) has been effectively wound down in active U.S. commercialization, leaving only reactive ordering under EUA/exceptional circumstances and implying any future U.S. or EU effort would likely need a partner. That shift sharply reduces near-term revenue visibility, especially given only about €29K of revenue against roughly €18.0M of SG&A expense in 2025, while the company still expects no profitability for several years and will likely need additional capital on uncertain terms. Beyond the financial strain, the pipeline carries substantial clinical, competitive, regulatory, and legal risk, with approved AAV therapies already established and InflaRx needing to prove differentiation across multiple indications such as izicopan and INF904.